Something almost all traders look for when it comes to trading penny stocks is a catalyst. They like to know the reason why certain stocks are moving the way they are. This might be a sector-related catalyst. It might also be a corporate-related catalysts. Then again, it might just be something obscure like we saw earlier this week from low float penny stocks, in general. Regardless of the fact, at the end of the day, understanding what could be the source of a move can help determine your trading strategy.
I talked about fundamental catalysts. These updates tend to reference something meaningful happening with a company. It might be a new drug study or closing a new deal with a client. It could also be bad news too. Think about how volatile things can become around earnings. For example, today, Coca Cola (KO Stock Report) reported earnings. Due to the coronavirus pandemic, investors have exercised caution when companies report financial results. However, in the case of KO stock, shares skyrocketed on Thursday morning after the company beat estimates. On the other hand, had those results missed estimates, it might’ve been a different story altogether.
The fact of the matter is that catalysts can play a big role in your approach to trading. Heading into the end of the week, there are a few things going on that might grab headlines and act as potential catalysts. We’ve got the last Presidential debates, a stimulus bill still up in the air, and plenty of economic data to sift through. With all of this in mind, Here are several penny stocks to watch during the second half of this week.Penny Stocks To Watch: GT Biopharma Inc.
GT Biopharma Inc. (GTBP Stock Report) has become synonymous with headline momentum recently. The broader focus for the company is on its TriKE™ treatment platform. TriKE™ is a combination protein that bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially. It has led to new first-in-human phase studies to treat leukemia and has indications for other type of cancers under evaluation. While recent headlines focus on the treatment platform itself, there’s also plenty of focus on GT’s lead candidate GTB-3550 initially indicated for the treatment of acute myeloid leukemia.
Several weeks ago, momentum began building after the company announced completion of the treatment of its first patient enrolled at Dose Level 3. This was in its GTB-3550 TriKE™ Phase I/II clinical trial. GTB-3550 at a 25mcg/kg/day dose showed a decrease in AML blast levels from 18% to 12% in the bone marrow. GT biopharma also saw improvement in marrow cellularity and platelet and red blood cell numbers. There’s also several upcoming dates to keep in mind with GT Biopharma centered on GTB-3550.What To Watch With GT Biopharma
Its abstract “GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts” has been selected by the Program Committee for presentation in an Oral Session at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on December 5th.
In addition to the presentation, the company explained that an abstract will also be published online in the November supplemental issue of the journal Blood. The first publication will be in the online ASH meeting program on November 5, 2020. Furthermore, “NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo” was recently published. This was in the journal Cancers, volume 12, issue 9, page 2659; (https://doi. org/10.3390/cancers12092659).
“The findings presented indicate that a B7H3-targeted TriKE™ has the potential to enhance natural killer (NK) cell immunotherapy in solid tumor settings, and supports its further clinical development.”Penny Stocks To Watch: Bio-Path Holdings Inc.
Bio-Path Holdings Inc. (BPTH Stock Report) is a company we’ve discussed in the past. In general, however, there hasn’t been much strength in its overall trend. A few days here and there BPTH stock broke out. However, the trend since July has been clearly bearish. Needless to say, Thursday saw another spark of momentum in the stock, taking it higher during premarket trading.
- 4 Top Penny Stocks To Watch Right Now; 2 Up Over 50% This Week
- Are These The Best Penny Stocks To Buy Right Now After Tesla Earnings?
Bio-Path announced that the United States Patent and Trademark Office issued a notice of allowance for claims related to prexigebersen. This is its lead product candidate. Prexigebersen is a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).What To Watch With Bio-Path Holdings
The new development provides protection for the application of prexigebersen to treat several cancers. While it isn’t standalone, the treatment would be in combination with other front-line therapies.
“Bio-Path is currently in an ongoing Phase 2 clinical trial of prexigebersen in combination with decitabine as a treatment for acute myeloid leukemia, and this new patent protects the unique therapy combination and supports our ongoing investment in this program to bring a new treatment option to patients with AML who have limited treatment options”Peter Nielsen, President and Chief Executive Officer of Bio-Path HoldingsPenny Stocks To Watch: Adial Pharmaceuticals Inc.
Adial Pharmaceuticals Inc. (ADIL Stock Report) is another one of the penny stocks we’ve discussed previously. Shares surged a few weeks ago after the company’s last big update. ADIL stock jumped from $1.41 to highs of $4 in a single day. Since then, the company’s shares slid.
What was the news? The FDA granted an emergency use authorization for Adial’s Covid-19 antibody test kit using fingerstick blood samples. The company said this is the first emergency use authorization for a serology point-of-care test for Covid-19 using fingerstick blood samples.What To Watch With Adial Pharmaceuticals
Another key update came out this week that has sent shares surging once again. Adial and Avalon GloboCare (AVCO Stock Report) announced a strategic collaboration. This is for global distribution of the Assure/Fastep® COVID-19 IgG/IgM Rapid Test device and the Assure/EcoStep® COVID-19 IgG/IgM Rapid Test device. These are point-of-care COVID-19 antibody tests.
“The FaStep COVID-19 IgG/IgM Rapid Test Device is the first serology (antibody) POC test for COVID-19 using fingerstick blood samples approved by the U.S. Food and Drug Administration (FDA), which has issued an emergency use authorization (EUA) for the FaStep COVID-19 IgG/IgM Rapid Test Device and the EcoStep COVID-19 IgG/IgM Rapid Test Device.”
Adial granted Avalon non-exclusive, sub-distribution rights worldwide for both tests.